VRDN vs. CSTL, FLGT, CDNA, CELC, VCYT, SERA, PMD, GH, ARWR, and FTRE
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Castle Biosciences (CSTL), Fulgent Genetics (FLGT), CareDx (CDNA), Celcuity (CELC), Veracyte (VCYT), Sera Prognostics (SERA), Psychemedics (PMD), Guardant Health (GH), Arrowhead Pharmaceuticals (ARWR), and Fortrea (FTRE). These companies are all part of the "medical" sector.
Castle Biosciences (NASDAQ:CSTL) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations.
Castle Biosciences has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
Castle Biosciences has higher revenue and earnings than Viridian Therapeutics. Castle Biosciences is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
92.6% of Castle Biosciences shares are held by institutional investors. 7.2% of Castle Biosciences shares are held by company insiders. Comparatively, 1.4% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Viridian Therapeutics had 23 more articles in the media than Castle Biosciences. MarketBeat recorded 37 mentions for Viridian Therapeutics and 14 mentions for Castle Biosciences. Viridian Therapeutics' average media sentiment score of 0.59 beat Castle Biosciences' score of 0.15 indicating that Castle Biosciences is being referred to more favorably in the media.
Castle Biosciences received 32 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 72.06% of users gave Viridian Therapeutics an outperform vote while only 62.31% of users gave Castle Biosciences an outperform vote.
Castle Biosciences has a net margin of -12.28% compared to Castle Biosciences' net margin of -75,737.85%. Viridian Therapeutics' return on equity of -7.91% beat Castle Biosciences' return on equity.
Castle Biosciences currently has a consensus price target of $31.57, suggesting a potential upside of 30.25%. Viridian Therapeutics has a consensus price target of $34.60, suggesting a potential upside of 148.92%. Given Castle Biosciences' higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Castle Biosciences.
Summary
Castle Biosciences beats Viridian Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
